US OptionsDetailed Quotes
TCRT241018P2500
- 1.15
- 0.000.00%
15min DelayTrading Feb 28 15:43 ET
0.00High0.00Low
0.00Open1.15Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover369.35%IV57.10%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier52DDays to Expiry1.15Extrinsic Value100Contract SizeAmericanOptions Type-0.1972Delta0.0646Gamma2.74Leverage Ratio-0.0113Theta-0.0021Rho-0.54Eff Leverage0.0032Vega
Alaunos Therapeutics Stock Discussion
Sign in to post a comment
$Alaunos Therapeutics (TCRT.US)$ Using "ghost"'shares today to send it down trying to get people to sell until they have shares available tomorrow to cover.
4
1
$Alaunos Therapeutics (TCRT.US)$ July 16th (Eastern Time) - $Alaunos Therapeutics (TCRT.US)$ is about to implement a 1-for-10 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from July 18th, 2024.
2
$Alaunos Therapeutics (TCRT.US)$ Yes, this has been on a great uptrend! Nice profits have been made! Now going forward its all speculative IMO! So an R/S has been voted on and approved. No date set but expected very soon, if the company actually decides to go through with it? Also Company cut its workforce by 80% to save money! As it stands they had cut one of its pretty successful drug trials ( TCR-T libra...
1
4
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Alaunos Therapeutics (TCRT.US)$ Alaunos wins bullish view at Wells Fargo on promise of cell therapy technology
2
$Alaunos Therapeutics (TCRT.US)$ TCR-T Library Phase 1/2 trial achievedan 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patients
No comment yet
Salmon Klein : in already master?